

10/06/2003

09831149.trn

=> d his

(FILE 'HOME' ENTERED AT 09:44:12 ON 06 OCT 2003)

FILE 'REGISTRY' ENTERED AT 09:44:26 ON 06 OCT 2003

L1 STRUCTURE UPLOADED

L2 6 S L1

L3 110 S L1 FUL

FILE 'CAPLUS' ENTERED AT 09:45:08 ON 06 OCT 2003

L4 13 S L3

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

59.39

207.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY



SESSION

CA SUBSCRIBER PRICE

-8.46

-8.46

STN INTERNATIONAL LOGOFF AT 09:45:44 ON 06 OCT 2003



chain nodes :

16

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

1-13 8-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14  
14-15

exact/norm bonds :

1-2 1-6 1-13 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-16 10-11 10-15 11-12 12-13  
13-14 14-15

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/Caplus records now contain indexing from 1907 to the  
present  
NEWS 4 Jul 15 Data from 1960-1976 added to RDISCLOSURE  
NEWS 5 Jul 21 Identification of STN records implemented  
NEWS 6 Jul 21 Polymer class term count added to REGISTRY  
NEWS 7 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and  
Right Truncation available  
NEWS 8 AUG 05 New pricing for EUROPATFULL and PCTFULL effective  
August 1, 2003  
NEWS 9 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 10 AUG 15 PATDPAFULL: one FREE connect hour, per account, in  
September 2003  
NEWS 11 AUG 15 PCTGEN: one FREE connect hour, per account, in  
September 2003  
NEWS 12 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in  
September 2003  
NEWS 13 AUG 15 TEMA: one FREE connect hour, per account, in  
September 2003  
NEWS 14 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 15 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 16 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Righ  
Truncation  
NEWS 17 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 18 SEP 22 DIPPR file reloaded  
NEWS 19 SEP 25 INPADOC: Legal Status data to be reloaded  
NEWS 20 SEP 29 DISSABS now available on STN  
  
NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:44:12 ON 06 OCT 2003

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:44:26 ON 06 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 OCT 2003 HIGHEST RN 598296-84-5

DICTIONARY FILE UPDATES: 3 OCT 2003 HIGHEST RN 598296-84-5

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09831149.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:44:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 8 TO 329

PROJECTED ANSWERS: 6 TO 266


L2 6 SEA SSS SAM L1

=> d scan

10/06/2003

09831149.trn

L2 6 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN  
IN 2 (3H) -Benzoxazolone, 7- [4- [(3,4-difluorophenyl)methyl] -1-piperazinyl] -  
(9CI)  
MF C18 H17 F2 N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

10/06/2003

09831149.trn

=> s l1 ful

FULL SEARCH INITIATED 09:45:05 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 246 TO ITERATE

100.0% PROCESSED 246 ITERATIONS  
SEARCH TIME: 00.00.01

110 ANSWERS

L3 110 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 09:45:08 ON 06 OCT 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Oct 2003 VOL 139 ISS 15  
FILE LAST UPDATED: 5 Oct 2003 (20031005/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 13 L3

=> d abs ibib hitstr 1-

YOU HAVE REQUESTED DATA FROM 13 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

AB The invention discloses the use of a compd. or a combination of compds. having partial dopamine D2 receptor agonistic activity and serotonin and/or noradrenaline reuptake inhibitory activity, for the prepn. of a pharmaceutical compn. for the treatment of psychiatric and/or neurol. disorders caused by disturbances of the major monoaminergic (dopamine, serotonin and/or noradrenaline) systems or that can be treated via manipulation of those systems.

ACCESSION NUMBER: 2003:652119 CAPLUS

DOCUMENT NUMBER: 139:173826

TITLE: Partial dopamine D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity for the treatment of psychiatric and/or neurological disorders

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336406	A1	20030820	EP 2002-76344	20020214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003068207	A2	20030821	WO 2003-EP50015	20030211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2002-76344 A 20020214

IT 269718-83-4, SLV 308 350992-10-8, Bifeprunox

452322-34-8 452322-35-9 577991-83-4

577991-84-5 577991-85-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(partial dopamine D2 receptor agonist with serotonin and/or noradrenaline inhibitory activity for treatment of psychiatric and/or neurol. disorders)

RN 269718-83-4 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl


RN 350992-10-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 452322-34-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[3-(5-fluoro-1-methyl-1H-indol-3-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 452322-35-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[3-(8-fluoro-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 577991-83-4 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[3-(5-fluoro-1H-indol-3-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 577991-84-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[3-(7-methyl-1H-indol-3-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 577991-85-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[3-(1H-indol-3-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

8


THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/06/2003

09831149.trn

L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
AB A review. This month's Annual Review is dedicated to updated information on neurol. drugs. The following table lists 154 drugs under development in this area, some of which have been published in previous issues of the journal and others that have been marketed for an indication other than that discussed in the review. Information on the following 28 products is updated here: cevimeline hydrochloride, CPI-1189, donepezil hydrochloride, ebselen, edaravone, etilevodopa, fampridine, FK-960, KW-6002, leteprinin potassium, modafinil, natalizumab, NXY-059, pregabalin, rasagiline mesilate, repinotan hydrochloride, retigabine, rivastigmine tartrate, rotigotine hydrochloride, safinamide mesilate, sapropterin dihydrochloride, SLV-308, stiripentol, T-588, talampanel, tomoxetine hydrochloride, xaliproden hydrochloride and zanzepzil fumarate.

ACCESSION NUMBER: 2002:966169 CAPLUS  
DOCUMENT NUMBER: 139:110860  
TITLE: Neurologic drugs  
AUTHOR(S): Mealy, N. E.; Castaner, R.; Martin, L.; del Fresno, M.; Revel, L.; Bayes, M.; Sorbera, L. A.; Cole, P.; Cullell-Young, M.; Leeson, P. A.; Prous, J.  
CORPORATE SOURCE: Spain  
SOURCE: Drugs of the Future (2002), 27(9), 879-915  
CODEN: DRFUD4; ISSN: 0377-8282  
PUBLISHER: Prous Science  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
IT 269718-83-4, SLV 308  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(updated annual review of neurol. drugs)  
RN 269718-83-4 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

REFERENCE COUNT: 172 THERE ARE 172 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 AB She present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (i) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (ii) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivs. thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amt. of said combination of therapeutic agents; and a pharmaceutical compn. comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package contg. a pharmaceutical compn. for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical compn. in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.

ACCESSION NUMBER: 2002:927246 CAPLUS  
 DOCUMENT NUMBER: 138:8349  
 TITLE: Combination of a dopamine D2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases  
 INVENTOR(S): Yeadon, Michael  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Germany  
 SOURCE: PCT Int. Appl., 122 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096422	A2	20021205	WO 2002-EP5642	20020523
WO 2002096422	A3	20030220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-293630P P 20010525  
 US 2001-303859P P 20010709

OTHER SOURCE(S): MARPAT 138:8349

IT 350992-10-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination of dopamine D2-receptor agonist and tiotropium or deriv. thereof for treating obstructive airways and other inflammatory diseases)

RN 350992-10-8 CAPLUS

10/06/2003

09831149.trn

CN 2(3H)-Benzoxazolone, 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
AB Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily affecting dopaminergic neurons arising from the substantia nigra pars compacta projecting to the caudate nucleus and putamen. The neurodegeneration of this pathway results in the primary symptoms of PD such as postural rigidity, bradykinesia and a resting tremor. In addn. to the motor abnormalities that are seen, many Parkinsonian patients also suffer from secondary symptoms such as depression, sleep disturbances and dementia which can affect quality of life indexes more than the primary motor abnormalities. We decided to develop candidate antiparkinsonian compds. combining partial dopamine D2 receptor agonism with full 5-HT1A receptor agonism. A range of compds. have been synthesized and tested in vitro and in animal models predictive of efficacy in Parkinson's disease and for potential antidepressant and anxiolytic-like efficacy. The non-ergot 7-(4-methyl-1-piperazinyl)-2(3H)-ben-zoxazolone monohydrochloride (SLV308) was selected as a compd. sharing potent partial dopamine D2 receptor agonism in combination with weaker full 5-HTA receptor agonism, ultimately providing an antiparkinsonian, antidepressant and anxiolytic-like profile. In the present chapter we assess some of the preclin. effects of SLV308 and other ref. compds. on putative indexes of in vitro receptor binding and functional activity and in vivo behavioral effects.

ACCESSION NUMBER: 2002:879590 CAPLUS  
DOCUMENT NUMBER: 139:46879  
TITLE: SLV308: a novel antiparkinsonian agent with antidepressant and anxiolytic properties  
AUTHOR(S): McCreary, Andrew G.; Ronken, Eric; Van der Heyden, Jan; Herremans, Arnoud; Tuinstra, Tinka; Long, Steve; Van Scharrenburg, Guus  
CORPORATE SOURCE: Solvay Research Laboratories, Solvay Pharmaceuticals, Weesp, Neth.  
SOURCE: Solvay Pharmaceuticals Conferences (2002), 1(Parkinson's Disease), 51-58  
CODEN: SPCOCJ; ISSN: 1566-7685  
PUBLISHER: IOS Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 269718-83-4, SLV 308  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(novel antiparkinsonian agent SLV308 with antidepressant and anxiolytic properties)  
RN 269718-83-4 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)

10/06/2003

09831149.trn



● HCl

REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 5 OF 13 ~~X~~ CAPLUS COPYRIGHT 2003 ACS on STN  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Phenylpiperazine derivs. I, II, useful for treating CNS disorders, in particular Parkinson's disease, are prepd.

ACCESSION NUMBER: 2002:658118 CAPLUS

DOCUMENT NUMBER: 137:203012

TITLE: Process for the preparation of phenylpiperazine derivatives useful in the treatment of Parkinson's disease

INVENTOR(S): Feenstra, Roelof W.; Ronken, Eric; Kruse, Cornelis G.; McCreary, Andrew C.; Van Scharrenburg, Gustaaf J. M.

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: PCT Int. Appl., 11 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066472	A1	20020829	WO 2002-EP1793	20020219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2002005220	A	20030624	BR 2002-5220	20020219
US 2003162791	A1	20030828	US 2003-343232	20030130
PRIORITY APPLN. INFO.:			EP 2001-200609	A 20010221
			WO 2002-EP1793	W 20020219

IT 452322-34-8P 452322-35-9P

RL: IMF (Industrial manufacture); PREP (Preparation)  
(process for the prepn. of phenylpiperazine derivs. useful in the treatment of Parkinson's disease)


RN 452322-34-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[3-(5-fluoro-1-methyl-1H-indol-3-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 452322-35-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[3-(8-fluoro-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




IT 105685-26-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
(process for the prepn. of phenylpiperazine derivs. useful in the treatment of Parkinson's disease)

RN 105685-26-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
GI



AB Piperazine and piperidine derivs. I [Y is hydrogen, halogen, alkyl (1-3C), or CN, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, alkoxy(1-3C), amino or mono- or dialkyl(1-3C) substituted amino or hydroxy; X is O, S, SO, SO<sub>2</sub>; Z represents -C, :C, -N; R<sub>1</sub>, R<sub>2</sub> independently represent hydrogen or alkyl (1-3C); Q is benzyl or 2-, 3- or 4-pyridylmethyl, which groups may be substituted with one or more more substituents from the group halogen, nitro, cyano, amino, mono- or di (1-3C)alkylamino, (1-3C) alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, SCF<sub>3</sub>, (1-4C)-alkyl, (1-3C)alkylsulfonyl, hydroxyl] were prepd. These compds. have pharmacol. properties due to a combination of (partial) agonism towards the members of the dopamine D<sub>2</sub>-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors (no data). E.g., I (Y = H, X = O, Z = N, R<sub>1</sub> = R<sub>2</sub> = H, Q = CH<sub>2</sub>Ph) was prepd.

ACCESSION NUMBER: 2001:833313 CAPLUS

DOCUMENT NUMBER: 135:357946

TITLE: Preparation of piperazine and piperidine compounds and their (partial) agonism towards the members of the dopamine D<sub>2</sub>-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors

INVENTOR(S): Feenstra, Roelof W.; Van Der Heijden, Johannes A. M.; Kruse, Cornelis G.; Long, Stephen K.; Van Scharrenburg, Gustaaf J. M.

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085725	A1	20011115	WO 2001-EP5320	20010510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1153925 A1 20011114 EP 2000-201699 20000512  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 EP 1283838 A1 20030219 EP 2001-938214 20010510  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2001010592 A 20030401 BR 2001-10592 20010510  
 US 2003119849 A1 20030626 US 2002-257677 20021015  
 NO 2002005365 A 20021108 ~~NO 2002-5365 20021108~~  
 PRIORITY APPLN. INFO.: EP 2000-201699 A 20000512  
 WO 2001-EP5320 W 20010510

OTHER SOURCE(S): MARPAT 135:357946


IT 372110-21-9P 372110-22-0P 372110-23-1P  
 372110-24-2P 372110-25-3P 372110-26-4P  
 372110-27-5P 372110-28-6P 372110-29-7P  
 372110-30-0P 372110-31-1P 372110-32-2P  
 372110-33-3P 372110-34-4P 372110-35-5P  
 372110-36-6P 372110-37-7P 372110-38-8P  
 372110-39-9P 372110-40-2P 372110-41-3P  
 372110-42-4P 372110-43-5P 372110-44-6P  
 372110-45-7P 372110-46-8P 372110-47-9P  
 372110-48-0P 372110-49-1P 372110-50-4P  
 372110-51-5P 372110-52-6P 372110-53-7P  
 372110-54-8P 372110-55-9P 372110-56-0P  
 372110-57-1P 372110-58-2P 372110-59-3P  
 372110-60-6P 372110-61-7P 372110-62-8P  
 372110-63-9P 372110-64-0P 372110-65-1P  
 372111-25-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperazine and piperidine compds. and their (partial) agonism towards the members of the dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors)


RN 372110-21-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-22-0 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-bromophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-23-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(pentafluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-24-2 CAPLUS


CN Benzonitrile, 4-[[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 372110-25-3 CAPLUS  
CN 2 (3H)-Benzoxazolone, 7-[4-[(3-methoxyphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-26-4 CAPLUS  
CN 2 (3H)-Benzoxazolone, 7-[4-[[4-(methanesulfonyl)phenyl]methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-27-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2,6-dichlorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-28-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-fluoro-3-methylphenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)



RN 372110-29-7 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(2,3-difluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)



RN 372110-30-0 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[[3-[(trifluoromethyl)thio]phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)






RN 372110-31-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2,5-dichlorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-32-2 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-methylphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-33-3 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(4-methoxyphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-34-4 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,4-difluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-35-5 CAPLUS

CN 2 (3H) -Benzoxazolone, 7- [4- [[4- (trifluoromethoxy)phenyl]methyl] -1-  
piperazinyl] - (9CI) (CA INDEX NAME)




RN 372110-36-6 CAPLUS

CN 2 (3H) -Benzoxazolone, 7- [4- [(3-bromophenyl)methyl] -1-piperazinyl] - (9CI)  
(CA INDEX NAME)




RN 372110-37-7 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3-bromo-4-methoxyphenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-38-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,4,5-trifluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-39-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2,4-difluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-40-2 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[2-(trifluoromethoxy)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-41-3 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-42-4 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3-methylphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-43-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-44-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,5-difluorophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 372110-45-7 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[[3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-46-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[4-(1,1-dimethylethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)







RN 372110-47-9 CAPLUS  
CN 2 (3H)-Benzoxazolone, 7-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-48-0 CAPLUS  
CN 2 (3H)-Benzoxazolone, 7-[4-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 372110-49-1 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-[4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-50-4 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-[4-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-51-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2,4,6-trifluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-52-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(4-bromophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-53-7 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-54-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-fluorophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-55-9 CAPLUS

CN Benzonitrile, 2-[[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 372110-56-0 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,5-dimethylphenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-57-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(4-methylphenyl)methyl]-1-piperazinyl] - (9CI)  
(CA INDEX NAME)




RN 372110-58-2 CAPLUS

CN Benzonitrile, 3-[[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl] - (9CI) (CA INDEX NAME)




RN 372110-59-3 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-60-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-chloro-4-fluorophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-61-7 CAPLUS  
CN 2 (3H)-Benzoxazolone, 7-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-62-8 CAPLUS  
CN 2 (3H)-Benzoxazolone, 7-[4-[(3-fluorophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)






RN 372110-63-9 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-(2-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-64-0 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-65-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-(4-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 372111-25-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3-chloro-2-fluorophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




IT 372110-70-8P 372110-73-1P 372110-74-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of piperazine and piperidine compds. and their (partial) agonism towards the members of the dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors)


RN 372110-70-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-hydroxy-1-(phenylmethyl)-4-piperidiny]- (9CI)  
(CA INDEX NAME)



RN 372110-73-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridiny]- (9CI)  
(CA INDEX NAME)




RN 372110-74-2 CAPLUS

10/06/2003

09831149.trn

CN 2(3H)-Benzoxazolone, 7-(4-piperidinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
GI



AB The invention discloses the use of compds. having combined dopamine D2 agonist activity, 5-HT1A agonist activity and .alpha.-adrenoceptor agonist activity for the treatment of CNS disorders, e.g. Parkinson's disease. Compds. of the invention include I [X = O, S, SO, SO<sub>2</sub>; Y = H, halo, C1-3 alkyl, etc.; ---Z = -C, =C, -N; R1, R2 = H, C1-3 alkyl; Q = (substituted) benzyl, (substituted) 2-, 3- or 4-pyridylmethyl]. Prepn. of selected I is described.

ACCESSION NUMBER: 2001:833089 CAPLUS  
DOCUMENT NUMBER: 135:352823  
TITLE: Use of compounds having combined dopamine D2, 5-HT1A and .alpha.-adrenoreceptor agonist action for treating central nervous system disorders  
INVENTOR(S): Van Der Heijden, Johannes A. M.; Long, Stephen K.; Feenstra, Roelof W.; Van Scharrenburg, Gustaaf J. M.  
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.  
SOURCE: PCT Int. Appl., 15 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085168	A1	20011115	WO 2001-EP5319	20010510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1153606	A1	20011114	EP 2000-201704	20000512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1284731	A1	20030226	EP 2001-945108	20010510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

10/06/2003

09831149.trn

US 2003186838 A1 20031002 ~~US 2002-275813~~ 20021112  
 PRIORITY APPLN. INFO.: EP ~~2000-201704~~ A 20000512  
 WO 2001-EP5319 W 20010510

OTHER SOURCE(S): MARPAT 135:352823


IT 372110-21-9P 372110-22-0P 372110-23-1P  
 372110-24-2P 372110-25-3P 372110-26-4P  
 372110-27-5P 372110-28-6P 372110-29-7P  
 372110-30-0P 372110-31-1P 372110-32-2P  
 372110-33-3P 372110-34-4P 372110-35-5P  
 372110-36-6P 372110-37-7P 372110-38-8P  
 372110-39-9P 372110-40-2P 372110-41-3P  
 372110-42-4P 372110-43-5P 372110-44-6P  
 372110-45-7P 372110-46-8P 372110-47-9P  
 372110-48-0P 372110-49-1P 372110-50-4P  
 372110-51-5P 372110-52-6P 372110-53-7P  
 372110-54-8P 372110-55-9P 372110-56-0P  
 372110-57-1P 372110-58-2P 372110-59-3P  
 372110-60-6P 372110-61-7P 372110-62-8P  
 372110-63-9P 372110-64-0P 372110-65-1P  
 372111-25-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(comps. with combined dopamine D2, 5-HT1A and .alpha.-adrenoreceptor agonist action for treating central nervous system disorders)


RN 372110-21-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-(phenylmethyl)-1-piperazinyl]-(9CI) (CA INDEX NAME)




RN 372110-22-0 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-bromophenyl)methyl]-1-piperazinyl]-(9CI)  
 (CA INDEX NAME)




RN 372110-23-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(pentafluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-24-2 CAPLUS

CN Benzonitrile, 4-[[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 372110-25-3 CAPLUS


CN 2 (3H)-Benzoxazolone, 7-[4-[(3-methoxyphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)



RN 372110-26-4 CAPLUS


CN 2 (3H)-Benzoxazolone, 7-[4-[[4-(methanesulfonyl)phenyl]methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)






RN 372110-27-5 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[(2,6-dichlorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-28-6 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[(2-fluoro-3-methylphenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-29-7 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2,3-difluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-30-0 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[3-[(trifluoromethyl)thio]phenyl]methyl]-1-  
piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-31-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2,5-dichlorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-32-2 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-methylphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-33-3 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[(4-methoxyphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-34-4 CAPLUS


CN 2 (3H)-Benzoxazolone, 7-[4-[(3,4-difluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)



RN 372110-35-5 CAPLUS  
CN 2 (3H)-Benzoxazolone, 7-[4-[[4-(trifluoromethoxy)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-36-6 CAPLUS  
CN 2 (3H)-Benzoxazolone, 7-[4-[(3-bromophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-37-7 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3-bromo-4-methoxyphenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-38-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,4,5-trifluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-39-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2,4-difluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-40-2 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[2-(trifluoromethoxy)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 372110-41-3 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)



RN 372110-42-4 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(3-methylphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)






RN 372110-43-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-44-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,5-difluorophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-45-7 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-46-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[4-(1,1-dimethylethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-47-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-48-0 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)



RN 372110-49-1 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-[4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-50-4 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-[4-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-51-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2,4,6-trifluorophenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-52-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(4-bromophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-53-7 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[(3,4-dimethylphenyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 372110-54-8 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[(2-fluorophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-55-9 CAPLUS

CN Benzonitrile, 2-[[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 372110-56-0 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3,5-dimethylphenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 372110-57-1 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(4-methylphenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)



RN 372110-58-2 CAPLUS


CN Benzonitrile, 3-[[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)






RN 372110-59-3 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 372110-60-6 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(2-chloro-4-fluorophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 372110-61-7 CAPLUS  
CN 2 (3H) -Benzoxazolone, 7- [4- [(4-fluorophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-62-8 CAPLUS  
CN 2 (3H) -Benzoxazolone, 7- [4- [(3-fluorophenyl)methyl]-1-piperazinyl]- (9CI)  
(CA INDEX NAME)




RN 372110-63-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-(2-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA  
INDEX NAME)




RN 372110-64-0 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA  
INDEX NAME)




RN 372110-65-1 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-(4-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 372111-25-6 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[(3-chloro-2-fluorophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




IT 372110-74-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(compds. with combined dopamine D2, 5-HT1A and .alpha.-adrenoreceptor  
agonist action for treating central nervous system disorders)

RN 372110-74-2 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(4-piperidinyl)- (9CI) (CA INDEX NAME)




IT 372110-70-8P 372110-73-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and reaction; compds. with combined dopamine D2, 5-HT1A and  
.alpha.-adrenoreceptor agonist action for treating central nervous  
system disorders)

RN 372110-70-8 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-hydroxy-1-(phenylmethyl)-4-piperidinyl]- (9CI)  
(CA INDEX NAME)



RN 372110-73-1 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]-  
(9CI) (CA INDEX NAME)



IT 105685-26-5  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction; compds. with combined dopamine D2, 5-HT1A and  
.alpha.-adrenoreceptor agonist action for treating central nervous  
system disorders)  
RN 105685-26-5 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 AB 1-Aryl-4-(biarylmethylene)piperazines were prepd. and their affinity for D2 and 5-HT1A receptors was detd.. A selection of these compds. was evaluated in vivo, resulting in the identification of a drug candidate which is being clin. evaluated as a potential atypical antipsychotic with reduced extrapyramidal side effects.

ACCESSION NUMBER: 2001:629000 CAPLUS  
 DOCUMENT NUMBER: 135:357896  
 TITLE: New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities

AUTHOR(S): Feenstra, R. W.; de Moes, J.; Hofma, J. J.; Kling, H.; Kuipers, W.; Long, S. K.; Tulp, M. T. M.; van der Heyden, J. A. M.; Kruse, C. G.

CORPORATE SOURCE: Research Laboratories, Solvay Pharmaceuticals, Weesp, 1380 DA, Neth.


SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(17), 2345-2349  
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


IT 197954-56-6P 350992-10-8P 373363-99-6P  
 373364-03-5P 373364-04-6P 373364-05-7P  
 373364-06-8P 373364-07-9P 373364-08-0P  
 373364-09-1P 373364-10-4P 373364-11-5P  
 373364-12-6P 373364-13-7P 373364-14-8P  
 373364-15-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities)

RN 197954-56-6 CAPLUS  
 CN 2 (3H)-Benzoxazolone, 7-[4-[[3-(3-thienyl)phenyl]methyl]-1-piperazinyl]-(9CI) (CA INDEX NAME)




RN 350992-10-8 CAPLUS  
 CN 2 (3H)-Benzoxazolone, 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-(9CI) (CA INDEX NAME)



RN 373363-99-6 CAPLUS


CN 2 (3H)-Benzoxazolone, 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 373364-03-5 CAPLUS


CN 2 (3H)-Benzoxazolone, 7-[4-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]-1-methyl- (9CI) (CA INDEX NAME)






RN 373364-04-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3'-chloro[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 373364-05-7 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(3'-methoxy[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 373364-06-8 CAPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 3'-[[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 373364-07-9 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 3'-[[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 373364-08-0 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[3-(2-thienyl)phenyl]methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 373364-09-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2-fluoro[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 373364-10-4 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[6-(4-fluorophenyl)-2-pyridinyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 373364-11-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[2-(4-fluorophenyl)-4-pyridinyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 373364-12-6 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[(5-phenyl-3-pyridinyl)methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)




RN 373364-13-7 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[[4-(4-fluorophenyl)-2-pyridinyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 373364-14-8 CAPLUS

CN 2-(3H)-Benzoxazolone, 7-[4-[(6-hydroxy[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 373364-15-9 CAPLUS

CN 2-(3H)-Benzoxazolone, 7-[4-[(3'-methyl[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




IT 105685-26-5 221194-56-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities)


RN 105685-26-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 221194-56-5 CAPLUS

CN 2(3H)-Benzoxazolone, 3-methyl-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/06/2003

09831149.trn



L4 ANSWER 9 OF ~~13~~ CAPLUS COPYRIGHT 2003 ACS on STN  
AB A review with 5 refs. discusses the synthesis, pharmacol. actions, pharmacokinetics and metab., toxicol., and clin. studies of SLV308, as a compd. showing extremely potent partial dopamine D2 receptor agonism in combination with weaker full 5-HT1A agonism, ultimately providing an antiparkinsonian, antidepressant, and anxiolytic profile.


ACCESSION NUMBER: 2001:349938 CAPLUS  
DOCUMENT NUMBER: 135:266440  
TITLE: SLV308  
AUTHOR(S): Feenstra, R.; Ronken, E.; Koopman, T.; de Vries, M.; McCreary, A.; Stoker, M.; van Charldorp, K.; Long, S.; van Scharrenburg, G.  
CORPORATE SOURCE: Solvay Pharmaceuticals, Weesp, 1380 DA, Neth.  
SOURCE: Drugs of the Future (2001), 26(2), 128-132  
CODEN: DRFUD4; ISSN: 0377-8282  
PUBLISHER: Prous Science  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
IT 269718-83-4  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(synthesis and pharmacol. of dopamine D2 and 5-HT1A receptor agonist SLV308)  
RN 269718-83-4 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)-



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
GI



I

AB The title compds. [I; S1 = H, halo, alkyl, etc.; X = NR3, S, CH2, etc. (wherein R3 = H, alkyl; ...Z = :C or N); R1, R2 = H, alkyl; R1 and R2 together can form a bridge of 2-3 carbon atoms; R4 = H, alkyl; Q = Me, Et, Et substituted with one or more fluorine atoms, etc.] and their salts which have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities (no data) and therefore are useful in treating anxiety and/or depression, were prepd. E.g., a 2-step synthesis of I [S1, R1, R2, R4 = H; X = O; ...Z = :C; Q = Me], starting with N-Boc-3-fluoroaniline and N-methylpiperidone, was given.

ACCESSION NUMBER: 2000:351516 CAPLUS  
DOCUMENT NUMBER: 132:347590  
TITLE: Preparation of new piperazine and piperidine compounds  
INVENTOR(S): Toorop, Gerrit P.; Feenstra, Roelof W.; Van Der Heijden, Johannes A. M.; Mos, Johannes; Long, Stephen K.; Visser, Gerben M.; Kruse, Cornelis G.; Van Scharrenburg, Gustaaf J. M.; Toorop, Anne G.  
PATENT ASSIGNEE(S): Duphar International Research B.V., Neth.  
SOURCE: PCT Int. Appl., 17 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000029397	A1	20000525	WO 1999-EP8702	19991110
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9915293	A	20010807	BR 1999-15293	19991110
EP 1131308	A1	20010912	EP 1999-955980	19991110

10/06/2003

09831149.trn

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

JP 2002530276	T2	20020917	JP 2000-582384	19991110
AU 756470	B2	20030116	AU 2000-12709	19991110
NZ 511584	A	20030131	NZ 1999-511584	19991110
NO 2001002339	A	20010511	NO 2001-2339	20010511

PRIORITY APPLN. INFO.:

EP 1998-203871	A	19981113
WO 1999-EP8702	W	19991110

OTHER SOURCE(S): MARPAT 132:347590


IT 269718-81-2P 269718-82-3P 269718-83-4P

269718-84-5P 269718-85-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of new piperazine and piperidine compds.)

RN 269718-81-2 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(4-ethyl-1-piperazinyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)




544/367  
574/25462

● HCl


RN 269718-82-3 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(4-ethyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 269718-83-4 CAPLUS


CN 2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 269718-84-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 269718-85-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (9CI)  
(CA INDEX NAME)


546 / 209  
814 / 321

IT 269718-88-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of new piperazine and piperidine compds.)

RN 269718-88-9 CAPLUS

CN 2(3H)-Benzoxazolone, 7-(1,2,3,6-tetrahydro-4-pyridinyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 269718-86-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of new piperazine and piperidine compds.)

RN 269718-86-7 CAPLUS

CN 3(2H)-Benzoxazolecarboxylic acid, 2-oxo-7-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
GI



I

AB Title compds. [I; Q = CH<sub>2</sub>CR<sub>5</sub>R<sub>6</sub>ZR<sub>7</sub>; R, R<sub>3</sub>, R<sub>4</sub> = H or alkyl; R<sub>1</sub> = H or F; R<sub>2</sub> = H, alkyl, oxo (sic); R<sub>5</sub>, R<sub>6</sub> = H, alkyl, alkylphenyl; R<sub>7</sub> = cyclic group (sic), (hetero)aryl, adamantyl, etc.; T = N or C (sic); Y = C, O, N, or S (sic); Z = CH<sub>2</sub>O, CH<sub>2</sub>CO, NHCO, etc.; Z<sub>1</sub> = (CR'')<sub>p</sub>; R'' = H or alkyl; Z<sub>2</sub> = (CH<sub>2</sub>)<sub>n</sub>; n = 1 or 2; p = 0-2; dashed lines = optional bond(s)] were prepd. Thus, 5-(1-piperazinyl)-1,2,3,4-tetrahydroquinoline was alkylated by Cl(CH<sub>2</sub>)<sub>3</sub>COC<sub>6</sub>H<sub>4</sub>F-4 to give I [Q = (CH<sub>2</sub>)<sub>3</sub>COC<sub>6</sub>H<sub>4</sub>F-4; R-R<sub>4</sub> = H, T = N, Y = Z<sub>1</sub> = Z<sub>2</sub> = CH<sub>2</sub>, dashed lines = null]. Data for biol. activity of I were given.

ACCESSION NUMBER: 1999:176950 CAPLUS  
DOCUMENT NUMBER: 130:223299  
TITLE: Preparation of 5-piperazinotetrahydroquinolines and analogs as 5-HT<sub>1</sub> receptor agonists  
INVENTOR(S): Feenstra, R. W.; Visser, G. M.; Kruse, C. G.; Tulp, M. T. M.; Long, S. K.  
PATENT ASSIGNEE(S): Duphar International Research B.V, Neth.  
SOURCE: Eur. Pat. Appl., 26 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 900792	A1	<del>19990310</del>	EP 1998-202832	19980824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2246126	AA	19990302	CA 1998-2246126	19980828
JP 11147871	A2	19990602	JP 1998-259105	19980831
US 6214829	B1	20010410	US 1998-144076	19980831
PRIORITY APPLN. INFO.:			EP 1997-202704	A 19970902
OTHER SOURCE(S): MARPAT 130:223299				
IT 221193-59-5P 221193-60-8P 221193-61-9P				
221193-64-2P 221193-65-3P 221193-70-0P				
221193-72-2P 221193-73-3P 221193-75-5P				
221193-76-6P 221193-78-8P 221193-79-9P				
221193-84-6P 221193-86-8P 221193-87-9P				

**221194-08-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 5-piperazinotetrahydroquinolines and analogs as 5-HT1 receptor agonists)


RN 221193-59-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[3-(4-fluorophenoxy)propyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 221193-60-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[4-(4-fluorophenyl)-4-oxobutyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




10/06/2003

09831149.trn

RN 221193-61-9 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[3-(cyclohexyloxy)propyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 221193-64-2 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[3-(4-fluorophenoxy)-2-methylpropyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




● HCl

RN 221193-65-3 CAPLUS  
CN 2(3H)-Benzoxazolone, 7-[4-[3-(4-fluorophenoxy)butyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



HCl


RN 221193-70-0 CAPLUS

10/06/2003


09831149.trn

CN 2(3H)-Benzoxazolone, 7-[4-[2-[(4-fluorophenyl)methoxy]ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 221193-72-2 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[4-(4-fluorophenyl)-4-(methoxyimino)butyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 221193-73-3 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[4-(4-fluorophenyl)-3-methyl-4-oxobutyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 221193-75-5 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[3-(4-fluorophenoxy)propyl]-1-piperazinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 221193-76-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2R)-3-(4-fluorophenoxy)-2-methylpropyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 221193-78-8 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(2S)-4-(4-fluorophenyl)-2-methyl-4-oxobutyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 221193-79-9 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(2S)-3-(4-fluorophenoxy)-2-methylpropyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221193-84-6 CAPLUS  
CN Benzamide, N-[2-[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]ethyl]-  
4-fluoro- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 221193-86-8 CAPLUS

CN Benzamide, N-[2-[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]ethyl]-  
2-fluoro- (9CI) (CA INDEX NAME)


RN 221193-87-9 CAPLUS

CN Benzamide, N-[2-[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]ethyl]-  
2,4-difluoro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 221194-08-7 CAPLUS  
CN Benzamide, N-[(1R)-2-[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]-1-methylethyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






IT 105685-26-5 221194-56-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 5-piperazinotetrahydroquinolines and analogs as 5-HT1  
receptor agonists)


RN 105685-26-5 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 221194-56-5 CAPLUS

CN 2 (3H)-Benzoxazolone, 3-methyl-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
GI



AB Title compds. [I; R = CH<sub>2</sub>Z<sub>2</sub>R<sub>5</sub>; R<sub>1</sub> = H or F; R<sub>3</sub>, R<sub>4</sub> = H or alkyl; R<sub>5</sub> = (un)substituted Ph, -furyl, -thienyl; R<sub>6</sub>, R<sub>7</sub> = atoms to complete a (un)substituted heterocyclic ring; Z = C or N; Z<sub>1</sub> = CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>; Z<sub>2</sub> = 1,3-phenylene; dashed line = bond when Z = C and = null when Z = N] were prepd. Thus, 1-(3,4-dihydrobenzodioxepin-6-yl)piperazine was condensed with 3-bromomethylbiphenyl to give title compd. II. Data for biol. activity of I were given.

ACCESSION NUMBER: 1997:679080 CAPLUS

DOCUMENT NUMBER: 127:331506

TITLE: Preparation of 1-biphenylmethyl-4-heteroarylpiperazines and analogs as nervous system agents

INVENTOR(S): Feenstra, Roelof Willem; Kruse, Cornelis Gerrit; Tulp, Martinus Theodorus Maria; Kuipers, Wilma; Long, Stephen Kenneth; et al.

PATENT ASSIGNEE(S): Duphar International Research B.V., Neth.; Feenstra, Roelof Willem; Kruse, Cornelis Gerrit; Tulp, Martinus Theodorus Maria; Kuipers, Wilma; Long, Stephen Kenneth

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736893	A1	19971009	WO 1997-EP1461	19970320
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

10/06/2003

09831149.trn

CA 2250347	AA	19971009	CA 1997-2250347	19970320
AU 9720294	A1	19971022	AU 1997-20294	19970320
AU 708053	B2	19990729		
EP 889889	A1	19990113	EP 1997-908288	19970320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1215400	A	19990428	CN 1997-193520	19970320
CN 1100055	B	20030129		
BR 9708389	A	20000104	BR 1997-8389	19970320
NZ 331860	A	20000428	NZ 1997-331860	19970320
JP 2000507949	T2	20000627	JP 1997-534886	19970320
RU 2178414	C2	20020120	RU 1998-119523	19970320
ZA 9702639	A	19971002	ZA 1997-2639	19970326
TW 422846	B	20010221	TW 1997-86104056	19970328
NO 9804533	A	19981102	NO 1998-4533	19980928
KR 2000005412	A	20000125	KR 1998-708145	19980929
US 6225312	B1	20010501	US 1999-155608	19990304

PRIORITY APPLN. INFO.:

EP 1996-200864	A	19960329
WO 1997-EP1461	W	19970320


OTHER SOURCE(S): MARPAT 127:331506

IT 197954-51-1P 197954-55-5P 197954-56-6P  
 197954-57-7P 197954-66-8P 197954-67-9P  
 197954-68-0P 197954-69-1P 197954-70-4P  
 197954-71-5P 197954-72-6P 197954-77-1P  
 197954-85-1P 197955-12-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 1-biphenylmethyl-4-heteroaryl piperazines and analogs as nervous system agents)

RN 197954-51-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


RN 197954-55-5 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[3-(2-thienyl)phenyl]methyl]-1-piperazinyl]-,

10/06/2003

09831149.trn


monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 197954-56-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[[3-(3-thienyl)phenyl]methyl]-1-piperazinyl]-  
(9CI) (CA INDEX NAME)



RN 197954-57-7 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(6-methoxy[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 197954-66-8 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 197954-67-9 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(3'-chloro[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 197954-68-0 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(3'-methoxy[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 197954-69-1 CAPLUS


CN 2(3H)-Benzoxazolone, 7-[4-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 197954-70-4 CAPLUS


CN [1,1'-Biphenyl]-3-carbonitrile, 3'--[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 197954-71-5 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 3'--[4-(2,3-dihydro-2-oxo-7-benzoxazolyl)-1-piperazinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 197954-72-6 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-[(4-fluoro[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 197954-77-1 CAPLUS

CN 2(3H)-Benzoxazolone, 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 197954-85-1 CAPLUS


CN 2 (3H)-Benzoxazolone, 7-[4-[(6-hydroxy[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 197955-12-7 CAPLUS

CN 2 (3H)-Benzoxazolone, 7-[4-[(3'-methyl[1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 GI For diagram(s), see printed CA Issue.  
 AB The title compds. (I; R1 = alkyl, cycloalkyl, alkoxyalkyl, etc.; p = 0-3; R2 = alkyl; n and q = 0 or 1; R3 = alkylidene, oxo, thioxo, etc.; m = 0-2; A = 5-7 member ring contg. 1-3 O, S, or N), useful as psychotropics, are prepd. Thus, 1-[5-(1,4-benzodioxanyl)]piperazine-HCl was prepd. by treating 5-amino-1,4-benzodioxane with bis(2-chloroethyl)amine-HCl. No pharmacol. activities are described.

ACCESSION NUMBER: 1987:5080 CAPLUS  
 DOCUMENT NUMBER: 106:5080  
 TITLE: Preparation of piperazines as psychotropics  
 PATENT ASSIGNEE(S): Duphar International Research B. V., Neth.  
 SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61152655	A2	19860711	JP 1985-285841	19851220
EP 189612	A1	19860806	EP 1985-202085	19851216
EP 189612	B1	19921104		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 81975	E	19921115	AT 1985-202085	19851216
DK 8505860	A	19860622	DK 1985-5860	19851217
AU 8551391	A1	19860626	AU 1985-51391	19851218
AU 588015	B2	19890907		
ZA 8509663	A	19860827	ZA 1985-9663	19851218
ES 550104	A1	19861216	ES 1985-550104	19851218
CA 1271475	A1	19900710	CA 1985-497977	19851218
IL 77395	A1	19910816	IL 1985-77395	19851219
US 5424313	A	19950613	US 1993-135189	19931012
PRIORITY APPLN. INFO.:			NL 1984-3917	19841221
			EP 1985-202085	19851216
			US 1985-810094	19851218
			US 1988-161240	19880218
			US 1988-268886	19881108
			US 1990-471694	19900126
			US 1990-593280	19901005
			US 1991-802715	19911206
			US 1993-3683	19930113
IT 105684-76-2P 105685-26-5P				
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as psychotropic)				
RN 105684-76-2 CAPLUS				
CN 2(3H)-Benzoxazolone, 7-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)				



2 HCl

RN 105685-26-5 CAPLUS

CN 2 (3H) -Benzoxazolone, 7-(1-piperazinyl) - (9CI) (CA INDEX NAME)

